Pfizer has halted the clinical trial of MET-224o, an oral obesity drug developed by D&D Pharmatech. The company cited strategy as the reason for the decision, not technology. The halt was reported on August 5, 2026, and the trial is now stopped.
On August 5, 2026, Pfizer halted the clinical trial of MET-224o, an oral obesity drug candidate developed by D&D Pharmatech. The decision to stop the trial was announced with a focus on strategy.
The drug in question is MET-224o, which D&D Pharmatech developed as an oral treatment for obesity. Pfizer had been conducting the trial, and the study has now been discontinued.
Pfizer cited strategy as the reason for the halt. The company stated that the decision was not based on technology involved in the drug. This indicates that the drug's platform or scientific approach was not the problem behind the trial's termination.
Instead, the stop came from strategic considerations on Pfizer's side. The drug's development by D&D Pharmatech remains a separate point from the trial's discontinuation. MET-224o continues to be the name of the candidate, even though the trial is no longer active.
MET-224o is described as an oral obesity drug. D&D Pharmatech is the developer of this molecule. The trial that Pfizer halted was specifically for this candidate.
The term 'o' appears as part of the drug's name. The report on the halt emphasized the contrast between strategy and technology. No technical failure was mentioned in connection with the decision.
Pfizer's action affects the trial of MET-224o as reported. The drug candidate is intended for oral use in treating obesity. Its trial status has changed to halted, and the reason cited is strategy, not technology.
The news of August 5, 2026, centers on Pfizer's choice to end the trial. The reason given was strategic, not technological. D&D Pharmatech's oral obesity drug MET-224o now has a halted trial.
Related reading: Wegovy Weight Loss Question Raised in 10-Word Market Report, GLP-1 Drugs Set to Reshape Bariatric Surgery, Not Replace It, Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall, Lilly earnings continue rise due to growth of Mounjaro, Zepbound sales.